Uveitis: contrasting the approaches in Japan and the United States

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To compare the approaches to uveitis in Japan and the United States. Methods: This report is based on the author’s personal experience, conversations with Japanese colleagues, and a literature search using the database of the US National Library of Medicine. Results: The frequencies of specific forms of uveitis vary between the two countries. Options for therapy are affected by government regulations and the impact of insurance carriers. In both countries, there is a stepwise approach to therapy beginning with topical corticosteroids and ultimately advancing to biologics. Despite the differences, the goals for therapy, disease control with minimal toxicity, are the same. Conclusions: Genetic, environmental, and regulatory differences impact the approach to uveitis. Despite these factors, the goal for therapy is essentially the same.

Original languageEnglish (US)
JournalJapanese Journal of Ophthalmology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Uveitis
Japan
Government Regulation
National Library of Medicine (U.S.)
Insurance Carriers
Therapeutics
Biological Products
Adrenal Cortex Hormones
Databases

Keywords

  • Behcet’s disease
  • Biologics
  • Japan
  • United States
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{32e449f32c13466a82668d96346f90c3,
title = "Uveitis: contrasting the approaches in Japan and the United States",
abstract = "Purpose: To compare the approaches to uveitis in Japan and the United States. Methods: This report is based on the author’s personal experience, conversations with Japanese colleagues, and a literature search using the database of the US National Library of Medicine. Results: The frequencies of specific forms of uveitis vary between the two countries. Options for therapy are affected by government regulations and the impact of insurance carriers. In both countries, there is a stepwise approach to therapy beginning with topical corticosteroids and ultimately advancing to biologics. Despite the differences, the goals for therapy, disease control with minimal toxicity, are the same. Conclusions: Genetic, environmental, and regulatory differences impact the approach to uveitis. Despite these factors, the goal for therapy is essentially the same.",
keywords = "Behcet’s disease, Biologics, Japan, United States, Uveitis",
author = "Rosenbaum, {James (Jim)}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10384-018-0633-2",
language = "English (US)",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Uveitis

T2 - contrasting the approaches in Japan and the United States

AU - Rosenbaum, James (Jim)

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: To compare the approaches to uveitis in Japan and the United States. Methods: This report is based on the author’s personal experience, conversations with Japanese colleagues, and a literature search using the database of the US National Library of Medicine. Results: The frequencies of specific forms of uveitis vary between the two countries. Options for therapy are affected by government regulations and the impact of insurance carriers. In both countries, there is a stepwise approach to therapy beginning with topical corticosteroids and ultimately advancing to biologics. Despite the differences, the goals for therapy, disease control with minimal toxicity, are the same. Conclusions: Genetic, environmental, and regulatory differences impact the approach to uveitis. Despite these factors, the goal for therapy is essentially the same.

AB - Purpose: To compare the approaches to uveitis in Japan and the United States. Methods: This report is based on the author’s personal experience, conversations with Japanese colleagues, and a literature search using the database of the US National Library of Medicine. Results: The frequencies of specific forms of uveitis vary between the two countries. Options for therapy are affected by government regulations and the impact of insurance carriers. In both countries, there is a stepwise approach to therapy beginning with topical corticosteroids and ultimately advancing to biologics. Despite the differences, the goals for therapy, disease control with minimal toxicity, are the same. Conclusions: Genetic, environmental, and regulatory differences impact the approach to uveitis. Despite these factors, the goal for therapy is essentially the same.

KW - Behcet’s disease

KW - Biologics

KW - Japan

KW - United States

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=85056998533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056998533&partnerID=8YFLogxK

U2 - 10.1007/s10384-018-0633-2

DO - 10.1007/s10384-018-0633-2

M3 - Article

C2 - 30460514

AN - SCOPUS:85056998533

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

ER -